Clinical trials
ER+ Breast Cancer clinical trials
Below are recruiting er+ breast cancer clinical trials, each written for real people, not researchers. We’re tracking 554 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06179303RecruitingPhase 2
Imaging to predict response to abemaciclib for advanced breast cancer
This trial tests if a special PET scan can predict how well the drug abemaciclib works for people with advanced hormone receptor-positive, HER2-negative breast cancer. If you qualify, you would receive abemaciclib and have imaging scans to see if your cancer responds.
St Louis, MissouriAges 18 years+ - NCT06176261RecruitingPhase 2
Datopotamab deruxtecan for breast cancer with brain spread
This trial tests a new drug called datopotamab deruxtecan for people with HER2-negative breast cancer that has spread to the brain. It looks at how well the drug works against brain metastases.
Miami, FloridaAges 18 years+ - NCT06150898RecruitingPhase 2
Ketorolac and pregabalin for estrogen receptor positive breast cancer before surgery
This trial tests whether two medications, ketorolac (a pain reliever) and pregabalin (a nerve pain drug), can help treat estrogen receptor (ER) positive breast cancer when taken before surgery. It may offer better pain control and possibly improve cancer outcomes.
Brussels, Brussels CapitalAges 18–70 - NCT06135714RecruitingPhase 3
Targeting limited breast cancer spread with focused therapy
This trial tests whether treating just the few spots where breast cancer has spread (called oligometastases) with radiation or surgery can help control the disease. It is for people whose cancer has spread to 3 or fewer places, each small in size, and who are healthy enough for local treatments.
Bunkyō-Ku, TokyoAges 18 years+ - NCT06106477Recruiting
Intermittent fasting for women with early breast cancer
This trial studies whether a 14-hour night fast and 10-hour eating window can improve inflammation markers and quality of life in women with HR+/HER2- early breast cancer. You would start the fasting routine within three months of beginning hormone therapy.
Milwaukee, WisconsinAges 18 years+ - NCT06123988Recruiting
Fasting and exercise for advanced breast cancer
This study looks at whether fasting overnight and/or doing exercise can help improve fatigue and other quality-of-life measures in women with advanced hormone receptor positive breast cancer who are already taking a CDK4/6 inhibitor. Participation may involve following a fasting or exercise plan for a period of time.
Phoenix, ArizonaAges 18 years+ - NCT06092892RecruitingPhase 2
Upfront targeted lymph node removal for early breast cancer
This trial is for women age 45 and older with early ER-positive breast cancer that has spread to the lymph nodes under the arm. It tests a surgery approach where the main tumor and only a few key lymph nodes (rather than many) are removed.
Los Angeles, CaliforniaAges 45 years+ - NCT06085742RecruitingPhase 2
CMC chemotherapy for early stage breast cancer
This trial tests a chemotherapy combination (CMC) for people with early-stage, hormone receptor-positive, HER2-negative breast cancer who have a high risk of recurrence. It aims to understand if this oral regimen is effective and tolerable.
Chicago, IllinoisAges 18 years+ - NCT06099769RecruitingPhase 2
Testing enzalutamide with or without mifepristone for AR-positive breast cancer
This trial tests if adding the drug mifepristone to the standard antiandrogen enzalutamide works better than enzalutamide alone or chemotherapy for people with a specific type of breast cancer that has androgen receptors. It aims to find a new targeted treatment option for triple-negative or ER-low breast cancer.
Birmingham, AlabamaAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Birmingham, AlabamaAges Any age - NCT05929768RecruitingPhase 3
Shorter chemo plus immunotherapy without anthracyclines for early TNBC
This Phase 3 trial tests whether a shorter course of chemotherapy plus immunotherapy can work as well as standard treatment for early-stage triple-negative breast cancer. It avoids anthracycline drugs and may help reduce exposure to those medicines if the shorter plan is effective and safe.
Birmingham, AlabamaAges 18 years+ - NCT06058377RecruitingPhase 3
Adding immunotherapy to chemo for stage II-III breast cancer
This trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy works better than chemo alone for people with hormone receptor positive, HER2 negative breast cancer that is stage II or III and has a high-risk genetic score (MammaPrint High Risk 2).
Birmingham, AlabamaAges 18 years+ - NCT03694756Recruiting
Testing special MRI to see tiny breast cancer structures
This study is testing whether a special MRI scan can help show tiny features inside breast tumors (TMEM). It’s mainly a “feasibility” study, meaning the team is checking if the scan can be done safely and clearly in different types of operable breast cancer.
The Bronx, New YorkAges 18 years+ - NCT06072612RecruitingPhase 3
Bria-IMT plus CPI vs standard care for advanced breast cancer
This trial tests a new combination of two immunotherapy drugs (Bria-IMT and a checkpoint inhibitor) against your doctor's choice of standard treatments. It is for people with advanced breast cancer that has spread and who have already tried several prior therapies.
Phoenix, ArizonaAges 18 years+ - NCT06064812RecruitingPhase 1/Phase 2
Testing a new drug for advanced ER-positive breast cancer
This trial tests an experimental oral drug (FWD1802) for women with a specific type of advanced breast cancer (ER-positive, HER2-negative) that has stopped responding to hormone therapy. It looks at whether the drug can slow or stop cancer growth, especially if you have an ESR1 mutation.
Hefei, AnhuiAges 18 years+ - NCT06062498RecruitingPhase 2
Elacestrant alone or with a CDK4/6 inhibitor for advanced breast cancer
This trial compares a new hormone therapy (elacestrant) to the same therapy combined with a CDK4/6 inhibitor (palbociclib, abemaciclib, or ribociclib) for people with a specific type of advanced breast cancer (ER-positive, HER2-negative) that has a mutation in the ESR1 gene. It aims to see if the combination works better than the single drug.
Chicago, IllinoisAges 18 years+ - NCT06072807RecruitingPhase 4
Brain imaging study for ER+ breast cancer with brain tumors
This trial tests a special PET scan called FES to see if it can detect estrogen receptors in brain metastases. It may help doctors better target treatment for people with ER+ breast cancer that has spread to the brain.
New York, New YorkAges 18 years+ - NCT04526587Recruiting
Study of breast cancer markers after CDK4/6 inhibitor treatment
This study looks at lab markers and clinical features in people with certain types of breast cancer who are being treated with, or have already been treated with a CDK4/6 inhibitor like abemaciclib (ciclib-based therapy). It aims to understand patterns that may help doctors better characterize breast cancer after these treatments.
Buffalo, New YorkAges 18 years+ - NCT06042569RecruitingPhase 2
Lower-dose chemo for older women with HER2-negative breast cancer
This trial tests whether a lower dose of two chemotherapy drugs (docetaxel and cyclophosphamide) works well for women 65 and older with early-stage HER2-negative breast cancer. The goal is to maintain effectiveness while reducing side effects in this group.
Duarte, CaliforniaAges 65 years+ - NCT05982496RecruitingPhase 2
PET/MRI scan for certain breast cancer types
This trial is studying if a special PET/MRI scan using a tracer called 18F FES can help doctors decide the best treatment for people with Luminal A or hormone-receptor-positive lobular breast cancer. The scan looks at estrogen receptors to see if your cancer might respond to hormone therapy.
Milan, MIAges 18 years+ - NCT05982093RecruitingPhase 2
Elacestrant with or without triptorelin for premenopausal breast cancer
This trial tests a new hormone-blocking pill (elacestrant) with or without a shot that temporarily stops ovaries (triptorelin) for premenopausal women with early-stage, hormone-sensitive breast cancer. It aims to find a gentler treatment option before surgery.
Badalona, BarcelonaAges 35 years+ - NCT05933395RecruitingPhase 2
Targeted treatment for ER+ breast cancer after CDK4/6 therapy
This Phase 2 study tests a genetically guided treatment plan for ER-positive breast cancer that has progressed after CDK4/6 therapy. It may help by matching treatment to tumor genetic changes.
Lebanon, New HampshireAges 18 years+ - NCT05919108RecruitingPhase 2
Neratinib before surgery for HER2-mutated invasive lobular breast cancer
This Phase 2 trial tests neratinib given before surgery to treat stage I–III invasive lobular breast cancer that has a specific HER2 mutation and is hormone-receptor positive. It may help shrink the tumor and improve control of cancer before and after surgery.
Atlanta, GeorgiaAges 18 years+ - NCT05901428RecruitingPhase 3
Check if two breast cancer treatments work better after surgery
This trial compares two treatment approaches in people with high-risk hormone-positive, HER2-negative breast cancer that has spread to certain lymph nodes. It looks at which option works best to lower cancer returning and to control the disease after surgery and initial chemotherapy.
Shanghai, Shanghai MunicipalityAges 18–70
Hear when a new ER+ Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for er+ breast cancer?
- Yes. Clin2 currently lists 554 recruiting er+ breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a er+ breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a er+ breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.